Valuation: AbbVie Inc.

Market Cap 465B 410B 388B 352B 660B 44,651B 666B 4,648B 1,791B 22,803B 1,747B 1,709B 73,241B P/E 2026 *
33.3x
P/E 2027 * 24.9x
Enterprise Value 527B 465B 440B 398B 748B 50,563B 754B 5,263B 2,028B 25,822B 1,978B 1,935B 82,936B EV / Sales 2026 *
7.79x
EV / Sales 2027 * 7.05x
Free-Float
95.71%
Yield 2026 *
2.63%
Yield 2027 * 2.74%
1 day-1.12%
1 week-0.45%
Current month+2.68%
1 month+3.06%
3 months+3.92%
6 months+25.74%
Current year+15.23%
1 week 261.52
Extreme 261.5213
269.39
1 month 246.77
Extreme 246.7701
269.39
Current year 190.75
Extreme 190.75
269.39
1 year 190.75
Extreme 190.75
269.39
3 years 135.85
Extreme 135.85
269.39
5 years 106.86
Extreme 106.86
269.39
10 years 55.06
Extreme 55.0623
269.39
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 Exercice

Executive/Senior Manager

98,130 0.0056%
6/30/26 Free

Director

62 0.0000%
6/30/26 Free

Director

134 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-1.12%-0.45%+19.35%+72.93% 471B
-0.01%+1.69%+63.50%+117.58% 1,056B
-1.61%-0.71%+48.89%+70.56% 655B
-1.72%-4.25%+37.79%+39.89% 342B
-0.40%+4.12%+22.89%+29.04% 277B
-0.51%-1.05%+12.98%+12.92% 257B
+1.32%+7.75%+55.19%+56.43% 226B
-0.61%+0.48%+34.95%+100.58% 189B
-0.24%-3.21%-27.79%-61.37% 170B
0.00%+3.53%+20.88%-10.50% 164B
Average -0.49%+0.66%+28.86%+42.81% 380.66B
Weighted average by Cap. -0.60%+0.81%+39.04%+65.51%

Financials

2026 *2027 *
Net sales 67.6B 59.62B 56.4B 51.11B 95.94B 6,488B 96.78B 675B 260B 3,313B 254B 248B 10,641B 73.5B 64.82B 61.32B 55.57B 104B 7,053B 105B 734B 283B 3,602B 276B 270B 11,569B
Net income 14.07B 12.41B 11.74B 10.64B 19.96B 1,350B 20.14B 141B 54.14B 689B 52.82B 51.67B 2,214B 19.05B 16.8B 15.89B 14.4B 27.03B 1,828B 27.27B 190B 73.31B 933B 71.52B 69.96B 2,998B
Net Debt 61.59B 54.32B 51.39B 46.57B 87.41B 5,911B 88.18B 615B 237B 3,019B 231B 226B 9,696B 53.09B 46.82B 44.29B 40.14B 75.35B 5,095B 76.01B 530B 204B 2,602B 199B 195B 8,357B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-09-29 US$263.29 -1.12% 3,878,551
26-09-28 US$266.28 +0.73% 4,429,512
26-09-25 US$264.34 -0.29% 2,541,718
26-09-24 US$265.12 +0.02% 3,458,166
26-09-23 US$265.08 -0.05% 3,469,242
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
266.28USD
Average target price
278.86USD
Spread / Average Target
+4.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABBV Stock